-
RedHill gets DSMB recommendation to continue Phase II/III Covid-19 study
pharmaceutical-technology
December 23, 2020
RedHill Biopharma has received a second unanimous DSMB recommendation to continue the global Phase II/III study of opaganib (Yeliva, ABC294640) in patients hospitalised with severe Covid-19 pneumonia.
-
RedHill to Continue Phase 2/3 COVID-19 Study with Opaganib
americanpharmaceuticalreview
December 04, 2020
RedHill Biopharma announced that the global Phase 2/3 study with opaganib (Yeliva?, ABC294640) in patients hospitalized with severe COVID-19 pneumonia has received a unanimous recommendation to continue, following a pre-scheduled safety review by an ...
-
Stem cell therapy trial for COVID-19 patients with ARDS advised to continue
europeanpharmaceuticalreview
November 13, 2020
The trial’s independent Data Safety Monitoring Board (DSMB) recommended that the Phase III study evaluating remestemcel-L continue based on the second interim analysis.
-
SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis
prnasia
November 09, 2020
SynAct Pharma AB, a clinical stage biopharmaceutical company developing novel therapies of inflammatory diseases, today announced that an independent Data Safety Monitoring Board (DSMB) has reviewed unblinded and validated data from part 1 of the ...
-
Humanigen announces positive interim data of Lenzilumab in hospitalised COVID-19 patients
expresspharma
November 09, 2020
The company intends to file for EUA in the first quarter of 2021 either following interim data at 75 per cent or at study completion.
-
BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen? Clinical Trial
biospace
March 08, 2018
?BioTime, Inc. announced that the independent Data Safety Monitoring Board (DSMB) has approved initiation of the fourth cohort for the ongoing OpRegen??clinical trial
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
